Inoue M
Department of Microbiology, Kitasato University, Sagamihara, Kanagawa, Japan.
J Chemother. 2002 Jul;14 Suppl 3:17-24. doi: 10.1080/1120009x.2002.11782348.
Because of increasing antimicrobial resistance in bacterial pathogens causing community-acquired respiratory tract infections (CARTIs), surveillance at local, regional, national and international levels is necessary to provide information to guide empiric antimicrobial therapy. PROTEKT (Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin) is a longitudinal, global, multicenter surveillance study designed to monitor the worldwide development of antimicrobial resistance, and disseminate up-to-date information via the internet to assist in the choice of empiric therapy at the local level. In this paper, the results for the first year of PROTEKT are presented from a local perspective. In examples from Japan, USA and Europe, great variation was observed between antimicrobial susceptibility patterns for Streptococcus pneumoniae, Streptococcus pyogenes and Haemophilus influenzae in countries and cities in close proximity to each other. Telithromycin demonstrated excellent in vitro activity against all organisms and is a potential new candidate for the empiric therapy of CARTIs. The first year of PROTEKT has provided valuable information on the prevalence of antimicrobial resistance of bacterial agents causing CARTIs that can be used for guiding empiric therapy and policies. Variation in local resistance observed in this study further emphasizes the need for accurate up-to-date surveillance data at the local level.
由于引起社区获得性呼吸道感染（CARTIs）的细菌性病原体的抗菌耐药性不断增加，因此有必要在地方、区域、国家和国际层面开展监测，以提供信息指导经验性抗菌治疗。PROTEKT（酮内酯类泰利霉素的前瞻性耐药菌跟踪与流行病学研究）是一项纵向、全球性、多中心监测研究，旨在监测全球抗菌耐药性的发展情况，并通过互联网传播最新信息，以协助地方层面选择经验性治疗方案。在本文中，将从地方视角呈现PROTEKT第一年的研究结果。在来自日本、美国和欧洲的实例中，彼此相邻的国家和城市中，肺炎链球菌、化脓性链球菌和流感嗜血杆菌的抗菌药敏模式存在很大差异。泰利霉素对所有病原体均表现出优异的体外活性，是CARTIs经验性治疗的潜在新候选药物。PROTEKT的第一年提供了有关引起CARTIs的细菌病原体抗菌耐药性流行情况的宝贵信息，可用于指导经验性治疗和制定相关政策。本研究中观察到的地方耐药性差异进一步凸显了地方层面获取准确最新监测数据的必要性。
